Unlock instant, AI-driven research and patent intelligence for your innovation.

Vaccine compositions for prevention against dengue virus infection

A technology of dengue virus, vaccine composition, applied in the direction of virus, vaccine, antiviral agent, etc.

Inactive Publication Date: 2015-07-29
SANOFI PASTEUR SA
View PDF35 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011]Due to the limited efficacy, difficulty and cost of dengue preventive measures such as mosquito control and personal protection from bites, a safe and effective dengue vaccine may be optimal prevention method
However, there are no currently available licensed vaccines of this type

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine compositions for prevention against dengue virus infection
  • Vaccine compositions for prevention against dengue virus infection
  • Vaccine compositions for prevention against dengue virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0256] Example 1 : 1-year follow-up of patients vaccinated with a tetravalent dengue vaccine (TDV) composition comprising Chimerivax® DEN-1, DEN-2, DEN-3, and DEN-4 in Thailand

[0257] method

[0258] Study Design and Participants

[0259] Against virologically proven dengue disease, for the quadrivalent Chimerivax® vaccine (i.e. containing specific CYD-1 strains generated from the prM and E sequences of DEN1 PU0359 (TYP 1 140), generated from the prM and E sequences of DEN2 PUO218 Tetravalent of specific CYD-2 strains, specific CYD-3 strains generated from the prM and E sequences of DEN3 PaH881 / 88, and specific CYD-4 strains generated from the prM and E sequences of DEN4 1228 (TVP 980) Vaccine, see WO 03 / 101397 and Guy et al., Vaccine (2011), 29(42): 7229-41 ) A randomized controlled single center Phase IIb trial blinded to the observer was conducted. A total of 4002 schoolchildren aged 4-11 years in good health based on medical history and physical examination...

Embodiment 2

[0307] Example 2 : Identification of an optimized dengue vaccine strain for serotype 2

[0308] The purpose of this example is to identify dengue virus strains of serotype 2, which provide the basis for generating an optimized dengue vaccine composition against dengue virus of serotype 2, wherein when used in the method of the present invention, with Chimerivax® CYD- 2, the optimized dengue vaccine composition provides improved efficacy.

[0309] Criteria for optimal strain selection for determining the worldwide dengue 2 antigen include: (i) recently circulating strains; (ii) balanced selection between Asian and American strains; (iii) optimized strains should have such a prM-E sequence that is as similar as possible to the calculated global consensus sequence generated by alignment of available prM-E sequences of dengue virus of serotype 2; (iv) should Avoid predicting amino acid variations that affect antibody recognition; (v) rare amino acids at specific positions in ...

Embodiment 3

[0393] Example 3: Construction of cDNA clones corresponding to optimized serotype 2 chimeric viruses and production of encoded viruses

[0394] Basically following the teaching of Chambers et al. (1999, J. Virology 73(4): 3095-3101), Chimerivax® technology was used to realize the construction of chimeric dengue virus equivalent to the optimized serotype 2 strain. Reference is also made to international patent applications WO 98 / 37911, WO 03 / 101397, WO 07 / 021672, WO 08 / 007021, WO 08 / 047023 and WO 08 / 065315, which describe in detail the methods for constructing CYD-1, CYD2, CYD -3 and a similar approach for CYD-4. Briefly however, a chimeric dengue virus equivalent to an optimized serotype 2 strain was constructed as follows (note: the optimized chimeric dengue virus used YF strain YF17D204 (YF-VAX(R), Sanofi-Pasteur, Swiftwater, PA, USA ) genome backbone construction).

[0395] Construction of plasmid pSP1101

[0396] Construction of YF-VAX cDNA clone-pJSY2284....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to vaccine compositions that are useful in a method of protecting a human subject against dengue disease.

Description

field of invention [0001] The present invention relates to a vaccine composition and the use of said composition in a method of protecting a human subject from dengue disease. Background of the invention [0002] Dengue is the second most important infectious tropical disease after malaria, with approximately half of the world's population living in areas at risk of epidemic transmission. Dengue hemorrhagic fever (DHF) causes 500,000 hospitalizations and approximately 25,000 deaths annually, with an estimated 50-100 million cases of dengue fever. [0003] Dengue disease infection is endemic in more than 100 tropical countries, and dengue hemorrhagic fever (DHF) has been confirmed in 60 of these countries (Gubler, 2002, TRENDS in Microbiology, 10: 100-103). [0004] Dengue disease is caused by four antigenically distinct but closely related dengue virus serotypes of the Flavivirus genus (Gubler et al., 1988, In: Epidemiology of arthropod-borne viral disease. Edited by M...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/12A61K39/295
CPCA61K2039/5258C12N2770/24134A61K2039/70A61K2039/53A61K2039/5254A61K2039/5252A61K39/12A61P31/14Y02A50/30A61P31/12A61K39/295C12N7/00
Inventor J.姚Y.吉雷尔-尚巴兹I.勒加斯特卢瓦N.曼特尔V.巴尔邦J.兰B.居伊
Owner SANOFI PASTEUR SA